StreetInsider.com News Articles

Form 8-K Amphastar Pharmaceutical For: Jun 01

Wed, 03 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26599054.html

Form 8-K Amphastar Pharmaceutical For: Jun 01

Wed, 03 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26599054.html

Amphastar Pharmaceuticals (AMPH) PT Lowered to $20 at Barclays

Wed, 03 Jun 2026 03:45:34 -0400

Barclays analyst Glen Santangelo lowered the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $20.00 (from $23.00) while maintaining a Equalweight rating.

Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference

Wed, 27 May 2026 06:00:00 -0400

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.

About Amphastar Pharmaceuticals, Inc.

Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and

Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference

Wed, 27 May 2026 06:00:00 -0400

About Amphastar Pharmaceuticals, Inc.

Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and

Wells Fargo Downgrades Amphastar Pharmaceuticals (AMPH) to Equal Weight

Thu, 14 May 2026 05:16:14 -0400

Wells Fargo analyst Benjamin Burnett downgraded Amphastar Pharmaceuticals (NASDAQ: AMPH) from Overweight to Equal Weight with a price target of $19.00.

For an analyst ratings summary and ratings history on Amphastar Pharmaceuticals click here. For more ratings news on Amphastar Pharmaceuticals click here.

Shares of Amphastar Pharmaceuticals closed at $18.32 yesterday.

Amphastar Pharmaceuticals (AMPH) PT Lowered to $21 at Piper Sandler

Mon, 11 May 2026 06:46:43 -0400

Piper Sandler analyst David Amsellem lowered the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $21.00 (from $25.00) while maintaining a Neutral rating.

Needham Downgrades Amphastar Pharmaceuticals (AMPH) to Hold

Fri, 08 May 2026 07:10:30 -0400

Needham analyst Serge Belanger downgraded Amphastar Pharmaceuticals (NASDAQ: AMPH) from Buy to Hold.

For an analyst ratings summary and ratings history on Amphastar Pharmaceuticals click here. For more ratings news on Amphastar Pharmaceuticals click here.

Shares of Amphastar Pharmaceuticals closed at $24.03 yesterday.

Amphastar Pharma (AMPH) Misses Q1 EPS by 30c

Fri, 08 May 2026 01:01:47 -0400

Amphastar Pharma (NASDAQ: AMPH) reported Q1 EPS of $0.42, $0.30 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $171.2 million versus the consensus estimate of $176.32 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

Form 10-Q Amphastar Pharmaceutical For: Mar 31

Thu, 07 May 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260507/26454752.html

Form 10-Q Amphastar Pharmaceutical For: Mar 31

Thu, 07 May 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260507/26454752.html

Form 8-K Amphastar Pharmaceutical For: May 07

Thu, 07 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260507/26454004.html

Form 8-K Amphastar Pharmaceutical For: May 07

Thu, 07 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260507/26454004.html

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Thu, 07 May 2026 16:05:00 -0400

Net revenues of $171.2 million for the three months ended March 31, 2026
GAAP net income of $6.4 million, or $0.14 per share, for the first quarter
Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter
Company to hold a conference call today at 2:00 p.m. Pacific Time

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Thu, 07 May 2026 16:05:00 -0400

Net revenues of $171.2 million for the three months ended March 31, 2026
GAAP net income of $6.4 million, or $0.14 per share, for the first quarter
Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter
Company to hold a conference call today at 2:00 p.m. Pacific Time

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

Wed, 06 May 2026 06:00:00 -0400

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.

About Amphastar Pharmaceuticals, Inc.

Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

Wed, 06 May 2026 06:00:00 -0400

About Amphastar Pharmaceuticals, Inc.

Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

Thu, 30 Apr 2026 06:00:00 -0400

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March 31, 2026, after the market closes on Thursday, May 7, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

To access the conference call, dial toll-free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.

The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

Thu, 30 Apr 2026 06:00:00 -0400

To access the conference call, dial toll-free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.

The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The

Jefferies Downgrades Amphastar Pharmaceuticals (AMPH) to Hold

Mon, 20 Apr 2026 16:28:08 -0400

Jefferies analyst Dennis Ding downgraded Amphastar Pharmaceuticals (NASDAQ: AMPH) from Buy to Hold with a price target of $22.00 (from $30.00).

For an analyst ratings summary and ratings history on Amphastar Pharmaceuticals click here. For more ratings news on Amphastar Pharmaceuticals click here.

Shares of Amphastar Pharmaceuticals closed at $22.88 yesterday.

Form ARS Amphastar Pharmaceutical For: Dec 31

Mon, 13 Apr 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260413/26306193.html

Form ARS Amphastar Pharmaceutical For: Dec 31

Mon, 13 Apr 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260413/26306193.html

Form DEFA14A Amphastar Pharmaceutical

Mon, 13 Apr 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260413/26306017.html

Form DEFA14A Amphastar Pharmaceutical

Mon, 13 Apr 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260413/26306017.html

Form DEF 14A Amphastar Pharmaceutical For: Jun 01

Mon, 13 Apr 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260413/26305897.html